Bayer AG is a German multinational life sciences company that generated $50.8 billion ($50.8 billion) in total group sales for fiscal year 2024 while executing the most aggressive corporate restructuring in its 162-year history. Founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott as a dyestuffs manufacturer, the company now employs approximately 92,815 people across 80+ countries and operates three divisions: Pharmaceuticals ($19.8 billion), Crop Science ($24.3 billion), and Consumer Health ($6.4 billion). Under CEO Bill Anderson, Bayer has cut over 12,000 positions, halved management ranks, and slashed its dividend to the legal minimum in a desperate bid to contain Roundup litigation costs exceeding $17.4 billion and execute a turnaround before its market value—already below the $66 billion Monsanto purchase price—erodes further.
Bayer AG: Key Facts
- Founded: August 1, 1863, in Barmen, Germany
- Headquarters: Leverkusen, North Rhine-Westphalia, Germany
- CEO: Bill Anderson (first American CEO, since June 2023)
- 2024 Group Sales: $50.8 billion ($50.8 billion)
- 2024 Net Loss: $2.8 billion
- 2024 EBITDA Before Special Items: $11.0 billion
- Employees: Approximately 92,815 as of December 31, 2024
- Market Cap: Approximately $38.7 billion ($38.7 billion)
- Divisions: Pharmaceuticals, Crop Science, Consumer Health
- Net Financial Debt: Approximately $36.0 billion
How Does Bayer Make Money?
Bayer generates revenue through three distinct divisions. Pharmaceuticals contributed $19.8 billion (38.9% of group sales) in 2024 from prescription drug sales and license fees. Key products include Nubeqa (darolutamide) for prostate cancer ($1.7 billion, +78% YoY), Xarelto (rivaroxaban) anticoagulant (declining due to generic competition), Eylea (aflibercept) for ophthalmology, and Kerendia (finerenone) for cardiovascular/renal disease (+67% YoY). The division has the highest margins, with EBITDA before special items of $5.1 billion (26.0% margin).
Crop Science generated $24.3 billion (47.8% of sales) from crop protection chemicals, seeds and traits, and digital agriculture solutions. Glyphosate-based herbicides (Roundup) remain the largest product line but declined 19% year-over-year due to Chinese generic competition. The division has lower margins (19.4% EBITDA margin) and faces structural headwinds from regulatory pressure to reduce chemical pesticide use. Consumer Health contributed $6.4 billion (12.6%) from over-the-counter brands including Aspirin, Aleve, Claritin, and Bepanthen, with stable but slow-growing revenues and 23.3% EBITDA margins.
Who Founded Bayer and When?
Bayer was founded on August 1, 1863, in Barmen, Germany (now part of Wuppertal), by Friedrich Bayer, a dye salesman, and Johann Friedrich Weskott, a master dyer. They established Farbenfabriken vorm. Friedr. Bayer & Comp. to manufacture synthetic fuchsine and aniline dyes for the textile industry. Friedrich Bayer's son, Friedrich Bayer Jr. (1851-1920), a chemist who joined in 1873, became the driving force behind the company's diversification into pharmaceuticals.
The pivotal moment came in 1897 when chemist Felix Hoffmann synthesized acetylsalicylic acid, leading to the 1899 trademark registration of Aspirin—the world's first mass-market synthetic drug. Bayer merged into IG Farben in 1925 and was re-established as an independent company in 1951 after the post-war dissolution. The company expanded through the Schering acquisition (2006, $15.9 billion), the Covestro spin-off (2015), and the transformative but disastrous Monsanto acquisition (2018, $66 billion).
What Is Bayer's Competitive Advantage?
Bayer's most defensible competitive moat is its 162-year brand equity and scientific credibility, built on the invention of aspirin in 1899 and sustained through generations of pharmaceutical innovation. The Bayer Cross is registered in over 80 countries, and aspirin generates over 10 billion tablets consumed annually. This brand commands physician attention, formulary access, and consumer trust that competitors cannot replicate within a decade.
In pharmaceuticals, Nubeqa's favorable CNS safety profile provides genuine clinical differentiation in prostate cancer. In Crop Science, the integrated seed-and-chemistry platform (Roundup Ready systems) creates switching costs for farmers. In Consumer Health, the Bayer brand generates price premiums in categories where consumers prioritize trusted names. The company's global manufacturing footprint, $6.8 billion R&D investment, and diversified revenue base provide further competitive defenses.
How Has Bayer's Revenue Grown Over Time?
Bayer's revenue trajectory reflects its strategic transformations. The company generated approximately $34.9 billion in 2006 before the Schering acquisition, then grew to $43.6+ billion by 2015. The Monsanto acquisition in 2018 added roughly $16.4 billion in annual agricultural revenues, pushing group sales above $46.9 billion. Revenues peaked at approximately $55.6 billion in 2021 before declining to $55.3 billion in 2022, $56.6 billion in 2023, and $50.8 billion in 2024.
The 2024 decline reflects currency effects (negative $1.5 billion), Xarelto generic erosion, and glyphosate price competition. The 2025 guidance of $49.1-47 billion implies further pressure. The revenue story is one of acquisition-driven growth followed by organic decline as legacy products face generic competition and structural market shifts.
Bayer Business Model Explained
Bayer operates a conglomerate business model with three distinct but interrelated divisions. Pharmaceuticals follows the classic branded drug model: high R&D investment, patent-protected pricing, and steep revenue cliffs upon generic entry. The division is currently experiencing a product mix shift—declining high-margin Xarelto replaced by growing but lower-margin new launches—that compresses margins. Crop Science operates a commodity-like model where prices are set by global agricultural markets, weather patterns, and farmer planting decisions rather than patent exclusivity. Consumer Health follows a consumer packaged goods model with stable, recurring revenues and lower margins.
The corporate model is under pressure. Cost of goods sold increased to 45.6% of sales in 2024 (from 41.5% in 2023), R&D rose 15.6% to $6.8 billion, and personnel expenses surged 16.5% to $13.6 billion despite headcount reductions. The Dynamic Shared Ownership transformation aims to reduce this cost burden by $2.2 billion annually by 2026.
Bayer Key Acquisitions
Bayer's most consequential acquisition is the $66 billion purchase of Monsanto in 2018, the largest by a German company in history. The deal made Bayer the global leader in agricultural inputs but triggered Roundup litigation that has cost over $17.4 billion and destroyed over 60% of shareholder value. The Monsanto brand was discontinued, and the acquisition is widely regarded as the worst corporate deal in German history.
The 2006 Schering acquisition ($15.9 billion) was financially successful, adding the Mirena franchise and establishing Bayer as a top-tier European pharmaceutical player. The 1994 purchase of Sterling Winthrop's OTC business ($1 billion) reclaimed the U.S. Bayer trademark rights lost during World War I. The 2015 Covestro spin-off ended Bayer's materials science presence to focus on life sciences.
What Are the Biggest Risks Facing Bayer?
The biggest risk is the Roundup litigation overhang, which has generated over 165,000 claims and cost $17.4+ billion. The Supreme Court declined to hear Bayer's appeal in 2022, eliminating the most promising path to favorable precedent. Without legislative caps on punitive damages, litigation costs could exceed $21.8 billion. Xarelto generic erosion removes $2.2-3 billion in annual EBITDA, and Chinese generic competition is permanently eroding glyphosate pricing. The balance sheet carries $36.0 billion in net financial debt against a $38.7 billion market cap, leaving minimal strategic flexibility. If Nubeqa and Kerendia growth disappoints, Bayer faces divisional divestitures or a breakup.
Bottom Line
Bayer is declining in the near term and betting everything on a high-risk turnaround. Revenues are guided to $49.1-47 billion in 2025 with EBITDA before special items of $10.4-10.0 billion, implying continued pressure. The company posted a net loss of $2.8 billion in 2024 and does not expect a rapid return to consistent profitability. Yet beneath the litigation overhang and generic erosion lies a pharmaceuticals division with genuine growth products: Nubeqa on track to exceed $3.3 billion in peak sales, Kerendia expanding into heart failure, and Eylea 8mg gaining traction. The question is whether these growth products can generate sufficient cash flow to fund litigation defense, debt reduction, and restructuring before the combination of legal costs and legacy product decline forces more drastic measures. Bayer is either European pharma's most compelling value opportunity or its most expensive cautionary tale—and the 2025-2027 execution of Anderson's five-priority transformation will determine which.
